文献速递眼底病与葡萄膜炎

二甲双胍使用与新发新生血管性年龄相关性黄斑变性风险的关联

ASSOCIATION OF METFORMIN USE WITH RISK OF NEWLY ONSET NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEVELOPMENT.
PubMed 文献 · Retina · 2024-01-01

这项病例对照研究纳入86,930例新诊断新生血管性年龄相关性黄斑变性(nAMD)患者和86,918例匹配对照,使用Merative Marketscan研究数据库分析。二甲双胍使用与nAMD风险降低相关(OR 0.95,95%CI 0.91-0.98),在无糖尿病视网膜病变的糖尿病患者中尤为明显,且24个月累积剂量低于1,080 g时均观察到该关联。

要点

  • 二甲双胍使用与nAMD风险降低相关(OR 0.95,95%CI 0.91-0.98)。
  • 在无糖尿病视网膜病变的糖尿病患者中,24个月累积剂量1-300 g、301-630 g、631-1,080 g均观察到风险降低。
  • 作者认为二甲双胍可能是nAMD的一种新型预防策略。

核心结论

  • 二甲双胍使用与nAMD风险降低相关,尤其在无糖尿病视网膜病变的患者中,24个月累积剂量低于1,080 g时可见保护效应。
  • 作者认为二甲双胍可能是nAMD的一种新型预防策略。

研究设计与样本

  • 病例对照研究,纳入86,930例新诊断nAMD患者和86,918例匹配对照,使用Merative Marketscan研究数据库,采用多因素条件logistic回归分析。
  • 另对22,117例糖尿病病例和21,616例糖尿病对照进行亚组分析。

主要发现

  • 全样本中,二甲双胍使用与nAMD风险降低相关(OR 0.95,95%CI 0.91-0.98)。
  • 糖尿病队列中同样观察到风险降低,尤其在无糖尿病视网膜病变的患者中,该效应经Bonferroni校正后仍持续存在。
  • 在无糖尿病视网膜病变的糖尿病队列中,24个月累积剂量1-300 g、301-630 g和631-1,080 g均观察到风险降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate if metformin use reduces the odds of developing new neovascular AMD (nAMD). METHODS: This is a case-control study of 86,930 subjects with new diagnoses of nAMD and 86,918 matched control subjects using the Merative Marketscan Research Databases. Subjects were analyzed using multivariable conditional logistic regression to identify the risks of various exposures on developing nAMD. A subgroup analysis of 22,117 diabetic cases and 21,616 diabetic control subjects was also performed. RESULTS: Metformin use was associated with reduced odds ratio of developing nAMD (odds ratio 0.95, 95% confidence interval 0.91-0.98) in full sample and diabetic cohort particularly in patients without any diabetic retinopathy-an effect that persisted after Bonferroni correction. In the diabetic cohort without diabetic retinopathy, reduced odds ratio was observed at 24-month cumulative doses of 1 to 300 g, 301 to 630 g, and 631 to 1,080 g. CONCLUSION: Metformin use was associated with reduced odds ratio of nAMD, particularly in patients without diabetic retinopathy. The protective effect was noted for 24-month cumulative doses below 1,080 g. Metformin may be a novel preventive strategy for nAMD.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Khanna S, Shaw L, Hyman MJ, et al. ASSOCIATION OF METFORMIN USE WITH RISK OF NEWLY ONSET NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEVELOPMENT. Retina. 2024. PMID: 38259182. doi:10.1097/IAE.0000000000003968

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。